TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) Director Mats Wahlstrom bought 50,000 shares of the business's stock in a transaction on Thursday, November 12th. The shares were acquired at an average cost of $2.24 per share, for a total transaction of $112,000.00. Following the transaction, the director directly owned 197,555 shares in the company, valued at approximately $442,523.20. This trade represents a 33.89% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.
TriSalus Life Sciences Price Performance
Shares of NASDAQ TLSI opened at $2.43 on Monday. The stock has a market capitalization of $149.63 million, a PE ratio of -4.96 and a beta of 0.50. The stock's fifty day simple moving average is $4.05 and its two-hundred day simple moving average is $4.29. TriSalus Life Sciences, Inc. has a 12-month low of $2.20 and a 12-month high of $7.95. The company has a current ratio of 4.22, a quick ratio of 3.86 and a debt-to-equity ratio of 47.60.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $12.88 million for the quarter, compared to analysts' expectations of $14.02 million. As a group, analysts expect that TriSalus Life Sciences, Inc. will post -0.62 EPS for the current fiscal year.
Analyst Ratings Changes
Several analysts have recently commented on the stock. Stifel Nicolaus set a $12.00 price objective on shares of TriSalus Life Sciences in a report on Wednesday, September 23rd. HC Wainwright cut their price target on TriSalus Life Sciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Wednesday, November 11th. Wall Street Zen lowered TriSalus Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday, November 7th. Guggenheim set a $12.00 target price on TriSalus Life Sciences in a research note on Wednesday, September 23rd. Finally, Zacks Research raised TriSalus Life Sciences to a "hold" rating in a report on Thursday, September 10th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $9.20.
Check Out Our Latest Research Report on TriSalus Life Sciences
Institutional Trading of TriSalus Life Sciences
A number of institutional investors and hedge funds have recently modified their holdings of TLSI. Cura Wealth Advisors LLC acquired a new position in shares of TriSalus Life Sciences during the second quarter valued at approximately $36,000. Russell Investments Group Ltd. purchased a new position in shares of TriSalus Life Sciences in the third quarter worth about $68,000. Provenance Wealth Advisors LLC acquired a new position in TriSalus Life Sciences during the third quarter worth about $94,000. Renaissance Technologies LLC acquired a new position in TriSalus Life Sciences during the first quarter worth about $124,000. Finally, Deutsche Bank AG purchased a new stake in TriSalus Life Sciences during the 2nd quarter valued at about $221,000. Hedge funds and other institutional investors own 2.58% of the company's stock.
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company's TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.